131I-MIBG therapy of neural crest tumours (review)

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1823-1831

  Troncone, Luigi ^a,b   Rufini, Vittoria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

131I MIBG; Neural crest tumours; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; (3 IODOBENZYL)GUANIDINE; IODOBENZENE; RADIOACTIVE IODINE;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CARCINOID; HUMAN; METASTASIS; NERVOUS SYSTEM TUMOR; NEURAL CREST; NEUROBLASTOMA; PANCYTOPENIA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; ADRENAL TUMOR; CLINICAL TRIAL; MEDULLARY CARCINOMA; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; REVIEW; THYROID TUMOR;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; CARCINOID TUMOR; CARCINOMA, MEDULLARY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; NEUROBLASTOMA; NEUROECTODERMAL TUMORS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; THYROID NEOPLASMS;

EID: 0030610283     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Wieland DM, Brown LE, Mangner TJ, et al: Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I-metaiodobenzylguanidine. J Nucl Med 21: 348-353, 1980.
2. Wafelman AR, Hoefnagel CA, Maes RAA, Beijnen JH: Radioiodinated metaiodobenzylguanidine: a review of pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21: 545-559, 1994.
3. Jacques S Jr, Tobes MC, Sisson JC, et al: Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 26: 539-546, 1984.
4. Shapiro B, Copp JE, Sisson JC, et al: Iodine-131 metaiodobenzylguanidine for the locating of suspected pheoehromocytoma: Experience in 400 cases. J Nucl Med 26: 576-585, 1985.
5. Geatti O, Shapiro B, Sisson JC, et al: Iodine131-metaiodobenzylguanidine for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 26: 736-742, 1985.
6. Troncone L, Rufini V, Danza FM et al: Radioiodinated metaiodobenzylguanidine (*I-MIBG) scintigraphy in neuroblastoma: a review of 160 studies. J Nucl Med Allied Sci 34: 279-288, 1990.
7. Troncone L, Rufini V, Montemitggi P, et al: The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur J Nucl Med 16: 325-335, 1990.
8. Hoefnagel CA, Voute PA, de Kraker J, et al: Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 28: 308-314, 1987.
9. Von Moll L, McEwan AJ, Shapiro B et al: Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheoehromocytoma and neuroblastoma. J Nucl Med 28: 978-988, 1987.
10. Baulieu JL, Guilloteau D, Delisle MJ et al: Radioiodinated metaiodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer 60: 2189-2194, 1987.
11. Feldman JM, Blinder RA, Lucas KJ et al: Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Mud 27: 1691-1696, 1986.
12. Sisson JC, Shapiro B, Beierwaltes WH, et al: Radiopharmaceutical treatment of malignant pheochromoeytoma. J Nucl Med 24: 197-206, 1984.
13. Bomanji J, Britton KE, Ur E, et al: Treatment of malignant pheochromocytoma and carcinoid tumours with 131I-metaiodobenzylguanidine. Nucl Med Commun 14: 856-861, 1993.
14. Troncone L, Galli G (eds): Proceedings of the International Workshop on ''The role of 131I-mstaiodobenzylguanidine in the treatment of neural crest tumors''. Rome (Italy). September 6-7, 1991. J Nucl Biol Med 35: 177-365, 1991.
15. Troncone L, Galli G (eds): Proceedings of the International Workshop on "Ten years of experience with MIBG applications and the potential of new radiolabelled peptides (particularly somatostatin analogs)". Rome (Italy), June 3, 1994. Q J Nucl Med 39 (suppl to n. 4): 1-156, 1995.
16. Mastrangelo R, Troncone L, Lasorella A, et al: 1311-metaiodobenzylguanidine in the treatment of neuroblastoma at diagnosis. Am J Pediatr Hematol Oncol 11: 28-31, 1989.
17. Hoefnagel CA, de Kraker J, Voute PA et al: Preoperative 131I-metaiodobenzylguanidine therapy of neuroblastoma at diagnosis (MIBG "de novo"). J Nucl Biol Med 35: 248-251, 1991.
18. Sisson JC, Hutchinson RJ, Shapiro B, et al: Iodine-125 MIBG to treat neuroblastoma: preliminary report. J Nucl Med 31: 1479-1485, 1991.
19. Sisson JC, Shapiro B, Hutchinson RJ, et al: Treatment of neuroblastoma with 1251-metaiodobenzylguanidine. J Nucl Biol Med 35: 255-259, 1991.
20. Loevinger R, Budinger TF, Watson EE: MIRD Primer for Absorbed Dose Calculations. New York, The Society of Nuclear Medicine 1988.
21. Ertl S, Deckart H, Blottner A, Tautz M, Radiopharmacokinetics and radiation absorbed dose calculations from 131I-metaiodobenzvl-guanidine (131I-MIBG). Nucl Med Commun 9: 643-653, 1987.
22. Shulkin B, Sisson JC, Koral KP, et al: Conjugate view gammacamera method for estimating tumor uptake of iodine-131 meta-iodobenzylguanidine. J Nucl Med 29: 542-548, 1988.
23. Khafagi FA, Shapiro B, Fig LM. et al: Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30: 481-489, 1989.
24. Hoefnagel CA, Lewington VJ, MIBG therapy. In: Nuclear Medicine in Clinical Diagnosis and Treatment: IPC Murray, PJ Ell (eds); p. 851-864, Churchill Livingstone, 1994.
25. Schlumberger M, Gicquel C, Lumbroso J et al: Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15: 631-642, 1992.
26. Krempf M, Lumbroso J, Mornex R, et al: Use of m-[131I]Iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 72: 455-461, 1991.
27. Shapiro B, Sisson JC, Wieland DM et al: Radiopharmaceutical therapy of malignant pheochromocytoma with 131I-metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35: 269-276, 1991.
28. Bestagno M, Pizzocaro C, Maira G, et al: Results of 131I-metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma. J Nucl Biol Med 35: 277-279, 1991.
29. Lewington, VJ, Zivanovic MA, Tristam M, et al: Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant pheochromocytoma. J Nucl Biol Med 280-283, 1991.
30. Krempf M, Lumbroso I, Mornex R, et al: Treatment of malignant phcochromocytoma with 131I-metaiodobenzylguanidine: A French multicentric study. J Nucl Biol Med 35: 284-287, 1991.
31. Lumbroso J, Schlumberger M, Tenebaum F et al: 1311-metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma. J Nucl Biol Med 35: 288-291, 1991.
32. Fischer M: Therapy of pheochromocytoma with 131I-mctaiodobenzylguanidine. J Nucl Biol Med 35: 292-294, 1991
33. Troncone L, Rufini V, Daidone MS et al: 1311-metaiodobenzylguanidine treatment of malignant pheochromocytoma: Experience of the Rome Group. J Nucl Biol Med 35: 295-299, 1991.
34. Colombo L, Lomuscio G, Vignati A et al: Preliminary results of 131I-metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma. J Nucl Biol Med 35, 300-304, 1991.
35. Schvartz C, Gibold C, Vuillemin B, et al: Results of 131I-metaiodobenzylguanidine therapy administered to three patients with malignant pheochromocytoma. J Nucl Biol Med 35: 305-307, 1991.
36. Hoefnagel CA, Schornagel J, Valdes Olmos RA: UM-metaiodbenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 35: 308-312, 1991.
37. Baulieu JL, Guilloteau D, Calais G, et al: 131I-metaiodobenzylguanidine treatment of a malignant paraganglioma. J Nucl Biol Med 35: 313-314, 1991.
38. Castellani MR, Rottoli L, Maffioli L et al: 1311-metaiodobenzylguanidine therapy in paraganglioma. 1 Nucl Biol Med 35: 315-317, 1991.
39. Khafagi F, Egerton-Vernon J, van Doom T, et al: Localization and treatment of familial malignant nonfunctional paraganglioma with Iodine-131 MIBG: report of two cases. J Nucl Med 28: 528-531, 1987.
40. Baulieu JL, Guilloteau D, Baulieu F et al: Therapeutic effectiveness of Iodine-131 MIBG metastases of a nonsecreting paraganglioma. J Nucl Med 29: 2008-2013, 1988.
41. Ball ABS, Tait DM, Fisher C, et al: Treatment of metastatic paraaortic paraganglioma by surgery, radiotherapy and 131I-mIBG. Eur J Surg Oncol 17: 543-546, 1991.
42. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and decarbazine. Ann Intern Med 109: 267-273, 1988.
43. Shapiro B: A review of the status of radio-iodinated MIBG therapy for neuroendocrine tumors. Internal Medicine 2: 61-68, 1994.
44. Ackery DM, Troncone L: Chairmen's Report: The role of 131I-metaiodobenzylguanidine in the treatment of malignant pheochromocytoma. J Nucl Biol Med 35: 318-320, 1991.
45. Matthay KK: An overview on the treatment of neuroblastoma. J Nucl Biol Med 35: 179-182, 1991.
46. Proceedings of the IV International Workshop in Pediatric Oncology on "The role of MIBG in Therapy, Diagnosis and Monitoring of Neuroblastoma" (Rome. Italy, September 22 and 23, 1986). Med Ped Oncol 75: 157-228, 1987.
47. Garaventa A, Guerra P, Arrighini A et al: Treatment of advanced neuroblastoma with 1-131 metaiodobenzylguanidine. Cancer 67: 922-928, 1991.
48. Hoefnagel CA, Voutc PA, deKraker J, et al: 131I-metaiodobcnzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 35: 202-205, 1991.
49. Hor G, Maul FD, Kornhuber B, et al: Outcome of 131I-mctaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med 35: 207-215, 1991.
50. Klingebiel T, Feine U, Treuner J, et al: Treatment of neuroblasioma with 131I-metaiodobenzylguanidine: Long-term resuks in 25 patients. J Nucl Biol Med 35: 216-219, 1991.
51. Lumbroso J, Hartmann O, Schlumberger M: Therapeutic use of 131I-metaiodobenzylguanidine in neuroblastoma: A phase II study in 26 patients. J Nud Biol Med 35: 220-223, 1991.
52. Claudiani F, Garaventa A, Bertolazzi L, et al: 1311 metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med 35: 224-227, 1991.
53. Corbett R, Pinkerton R, Tait D, et al: 131I-metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 35: 228-231, 1991.
54. Troncons L, Rufini V, Riccardi R, et al: The use of 131I-mctaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy. J Nucl Biol Med 35: 232-236, 1991.
55. Hutchinson RJ, Sisson JC, Miser JS, et al: Long-term results of 131I-metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 35: 237-240, 1991.
56. Castellani MR, Rottoli R, Maffioli , et al: Experience with palliative 131I metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med.35: 241-243, 1991.
57. Matthay KK, Huberty JP, Hattner RS. et al: Efficacy and safety of 131I-metaiodobenzylguanidine for patients with refractory neuroblastoma. J Nucl Biol Med 35: 244-247, 1991.
58. Sisson JC, Hutchinson RJ, Carey JE et al: Toxicity for treatment of neuroblastoma with 131I-meta-iodobenzyguanidine. Eur J Nucl 14: 337-340, 1988.
59. Sisson JC, Shapiro B, Hutchinson RJ et al: Predictor of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzyguanidine. Eur J Nucl Med 21: 46-52, 1994.
60. Rutgers M, Tytgat GAM, Verwijs-Janssen M, et al: Uptake of the neuro-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuroadrenergic tumour cells. Int J Cancer 54: 290-295, 1991.
61. Mastrangelo R, Lasorella A, Troncone L, et al: 131I- metaiodobenzylguanidine in neuroblastoma patients at diagnosis. J Nucl Biol Med 35: 252-254, 1991.
62. Hoefnagel CA, DeKraker J, Valdes Olmos RA, Voute PA: 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 15: 712-717, 1994.
63. Mastrangelo R, Lasorella A, Iavarone A et al: Clinical observations on neuroblastoma treatment with 131I-meta-iodobenzylguanidine at diagnosis. Med Ped Oncol 21: 411-415, 1993.
64. Troncone L, Rufini V, Tornesello A, Mastrangelo R: Attuali indirizzi nel trattamento radiometabolico del neuroblastoma con 131I-MIBG. .Riv Ital Ped (IJP) 21: 642-647, 1995.
65. Dewit L: Combined treatment of radiation and cis-diammine-dichloroplatinum (II): A review of experimental and clinical data. Int J Rad Oncol Biol Phys 13: 403-426, 1987.
66. Mastrangelo R, Tornesello A, Riccardi R et al: A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]-Meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 31A: 606-611, 1995.
67. Rufini V, Tornesello A, Festa A et al: Combined treatment of stage 4 neuroblastoma (NB) with I-131 MIBG and chemotherapy. J Nucl Med 37: 237P (abstract), 1996.
68. Mastrangelo R, Tornesello A,.Rufini V, et al: Treatment of stage IV neuroblastoma using a combination of I-131 MIBG and chemotherapy. Eur J Nucl Med 23: 1113 (abstract), 1996.
69. Marsh DJ, Learoyd DL, Robinson BG: Medullary thyroid carcinoma: recent advances and management update. Thyroid 5: 407-424, 1995.
70. Clarke SEM, Lazarus CR, Wraight P et al: Pentavalent 99mTc-DMSA, 131I-MIBG, and 99mTc-MDP. An evaluation of three imaging techniques in patients with medullary carcinoma ofthe thyroid. J Nucl Med 29: 33-38, 1988.
71. Troncone L, Rufini V, De Rosa G, et al: Diagnostic and therapeutic potential of new agents in medullary thyroid carcinoma. Henry Ford Hosp Med J 37: 178-84, 1989.
72. Clarke SEM: 131I-metaiodobenzylguanidine therapy in medullary thyroid cancer. Guy's Hospital experience. J Nucl Biol Med 35: 323-326, 1991.
73. Hoefnagel CA, Delprat CC, Valdes Olmos RA: Role of 131I-metaiodobenzylguanidine therapy in medullary thyroid carcinoma. J Nucl Biol Med 95: 334-336, 1991.
74. Scharvtz C, Delisle MJ: Results of 131I-metaiodobenzylguanidine therapy administered to two patients with medullary carcinoma of the thyroid . J Nud Biol Med 35: 332-333, 1991.
75. Troncone L, Rufini V, Maussier ML, et al: The role of 131I-metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: Results in five cases. J Nucl Biol Med 35: 327-331, 1991.
76. Peltier P, Curtet C, Chatal JF et al: Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an Indium-111-labeled DTPA dimer. J Nucl Med 34: 1267-1273, 1993.
77. Barbet J, Peltier P, Bardet S et al: Immunoscintigraphy of recurrent medullary thyroid carcinoma (MTC) using a bispecific antibody and an Indium-111-labeled bivalent hapten. A multicenter study of 42 patients with elevated thyrocalcitonin blood levels. J Nucl Med 36: 221P (abstract), 1995.
78. Bardet S, Bardies M, Faivre A et al: Imaging and dosimetry study using two-step injection of bispecific anti-carcinoembryonic antigen (CEA)/antiDTPA immunoconjugate (BSIC) and I-131 DTPA bivalent hapten in patients with medullary thyroid cancer (MTC). J Nucl Med 35: 41P (abstract), 1995.
79. Bomanji J, Levison DA, Zuzarte J, Britton KE. Imaging of carcinoid tumours with iodine 1231- metaiodobenzylguanidine. J Nucl Med 28: 1907-1910, 1987.
80. Bestagno M, Pizzocaro C, Pagliaini R, et al: Results of 131Imetaiodobenzylguanidine treatment in metastatic carcinoid. J Nucl Biol Med 35: 343-345, 1991.
81. Castellani MR, Di Bartolomeo M, Maffioli L, et al: 131I-metaiodobenzylguanidine therapy in carcinoid tumors. J Nucl Biol Med 35: 349-351, 1991.
82. Colombo L, Vignati A, Lomuscio G, et al: Preliminary results of 131I-metaiodobenzylguanidine treatment in metastatic carcinoid tumors. J Nucl Biol Med 35: 352-354, 1991.
83. Hoefnagel CA, Taal BG, Valdes Olmos RA: Role of 131I-metaiodobenzylguanidine therapy in carcinoids, J Nucl Biol Med 35: 346-348, 1991.
84. McEwan AJB: Treatment of patients with metastatic carcinoid tumor with 131I-metaiodobenzylguanidine (mIBG). International Workshop on "The role of 131I-metaiodobenzylguanidine in the treatment of neural crest tumors" (Rome, September 22 -and 23, 1991) Abstract Book p. 56.